AXIM Biotechnologies

March 8, 2017

AXIM Starts Phase 2 IBS Trial of CanChew Plus Cannabinoid-based Gum

News

AXIM Biotechnologies has enrolled 40 patients with irritable bowel syndrome (IBS) and initiated a Phase 2 clinical trial evaluating the effectiveness of its CanChew Plus cannabinoid (CBD)-based chewing gum for ... Read more

January 20, 2017

AXIM Begins Phase 2 Trial of Cannabinoid Chewing Gum for IBS Symptoms

News

AXIM Biotech has initiated a Phase 2 clinical trial evaluating the effectiveness of its CanChew Plus cannabinoid (CBD)-based chewing gum for alleviating symptoms of irritable bowel syndrome (IBS). In the case ... Read more